Skip to main content
BWAY
NASDAQ Industrial Applications And Services

BrainsWay Reports Strong Q1 2026 Growth, Reiterates Guidance, and Details Strategic Expansion

Analysis by Arik Shkolnikov
Sentiment info
Positive
Importance info
8
Price
$16.31
Mkt Cap
$675.405M
52W Low
$4.603
52W High
$17.352
Market data snapshot near publication time

summarizeSummary

BrainsWay reported strong Q1 2026 financial results with significant revenue and profit growth, reiterated its full-year guidance, and outlined strategic initiatives for market expansion and clinical pipeline advancement.


check_boxKey Events

  • Strong Q1 2026 Financial Results

    Revenue grew 35% year-over-year to $15.5 million, net income more than doubled to $2.3 million, and Adjusted EBITDA increased 117% to $2.8 million. The company shipped a record 117 Deep TMS systems, expanding its installed base to approximately 1,820 systems.

  • Reiterated Full-Year 2026 Guidance

    BrainsWay reaffirmed its full-year 2026 guidance, projecting revenue between $66 million and $68 million, an operating income margin of 13%-14%, and Adjusted EBITDA of $12 million to $14 million.

  • Expanded Payer Coverage and Market Access

    The company secured its first insurance coverage for the accelerated SWIFT™ Deep TMS protocol and expanded payer support for nurse practitioner-administered TMS. Cigna's Evernorth Behavioral Health will also eliminate prior authorization requirements for TMS coverage.

  • Strategic Investments and Partnerships for Growth

    BrainsWay expanded its strategic investment portfolio with additional investments in Neurolief, BrainStim Health, and Axis Management Company, holding 5 minority stakes. Valor Equity Partners is noted as a key strategic partner in the company's scale strategy.


auto_awesomeAnalysis

BrainsWay delivered robust Q1 2026 financial results, with significant revenue and net income growth, alongside strong Adjusted EBITDA. The company also reiterated its positive full-year 2026 guidance, signaling confidence in continued performance. Key strategic initiatives, including expanded payer coverage for its Deep TMS therapy, new strategic investments in mental health providers, and advancements in its clinical pipeline (such as the planned FDA submission for PTSD symptoms), are critical for driving future market penetration and revenue growth. The strong cash position further supports these expansion efforts.

At the time of this filing, BWAY was trading at $16.31 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $675.4M. The 52-week trading range was $4.60 to $17.35. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed BWAY - Latest Insights

BWAY
May 13, 2026, 4:01 PM EDT
Filing Type: 6-K
Importance Score:
8
BWAY
May 13, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
BWAY
Apr 20, 2026, 4:01 PM EDT
Filing Type: 20-F
Importance Score:
8
BWAY
Apr 15, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
BWAY
Mar 26, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
BWAY
Mar 11, 2026, 7:30 AM EDT
Filing Type: 6-K
Importance Score:
8
BWAY
Mar 05, 2026, 6:00 AM EST
Filing Type: 6-K
Importance Score:
8
BWAY
Feb 19, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
7
BWAY
Feb 18, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
8
BWAY
Jan 21, 2026, 7:30 AM EST
Filing Type: 6-K
Importance Score:
8